engClusa, LauraLatorre-Millán, MiriamMilagro, Ana MaríaTristancho-Baró, AlexanderLopez-Calleja, Ana IsabelGarcía-Lechuz, Juan ManuelFortuño, BlancaVillar, Nuno delAsensio, MarioMartín-Belloso, OlgaOdriozola-Serrano, IsabelMartínez-Beamonte RobertoOsada, JesúsRezusta, AntonioGilaberte, YolandaAntimicrobial activity and potential of Olive leaf extract as a topical agent to combat Staphylococcus aureus and MRSA strains: an in vitro evaluationART-2024-147129Background: Staphylococcus aureus is one of the most prevalent bacteria in skin and soft tissue infections (SSTIs). Multidrug-resistant strain emergence, particularly methicillin-resistant S. aureus (MRSA), highlights the need for alternative treatments. Objectives: This study investigates the antimicrobial properties of olive leaf extract (OLE) and describes an epidemiological profiling of patients with SSTI who may benefit from it. Methods: OLE was tested in two reference strains, methicillin-susceptible S. aureus (MSSA) ATCC 29213 and MRSA ATCC 700699, and in 126 clinical isolates from patients with SSTIs according to Clinical Laboratory Standards Institute guidelines. Results: The minimum bactericidal concentration (MBC) ranged from 3.12% to 6.25% w/v for MSSA and 1.56% to 3.12% for MRSA. The lethal curve showed a reduction of 6 log10CFU/mL after two hours of incubation. Most of the 126 clinical samples (103 MSSA and 23 MRSA) came from skin lesions, surgical wounds, and ulcers. Over 90% of MSSA strains were resistant to less than five antibiotics, while 82% of MRSA strains were resistant to more than six. Penicillins demonstrated the lowest susceptibility rate (19.8%), whereas linezolid, daptomycin, pristinamycin, trimethoprim–sulfamethoxazole, teicoplanin, vancomycin, and OLE exhibited 100% susceptibility. No growth was observed for all clinical strains with OLE at ≥6.25% w/v. Conclusions: The findings suggest that OLE could become a promising alternative treatment for skin infections, particularly in the context of increasing antibiotic resistance.2024http://zaguan.unizar.es/record/165728http://zaguan.unizar.es/record/165728oai:zaguan.unizar.es:165728info:eu-repo/grantAgreement/ES/CIBERObn/CB06-03-1012info:eu-repo/grantAgreement/ES/DGA/B10-23Rinfo:eu-repo/grantAgreement/ES/DGA/B16-23Rinfo:eu-repo/grantAgreement/ES/DGA/B59-23Dinfo:eu-repo/grantAgreement/ES/MICINN-AEI/PRTR-C17.I1info:eu-repo/grantAgreement/ES/MCINN/PID2022-136414OB-I00Pharmaceuticals 18, 9 (2024), 1358 [18 pp.]byhttps://creativecommons.org/licenses/by/4.0/deed.esinfo:eu-repo/semantics/openAccess